Caudal-Type Homeobox Transcription Factor 2 is a Favorable Prognostic Indicator in Stage II and III Gastric Cancer Following Curative Surgery
Yang Xu,Yue Wu,Jianhong Liu,Lili Xiao,Ying Zhang
DOI: https://doi.org/10.2147/ijgm.s471727
IF: 2.145
2024-09-28
International Journal of General Medicine
Abstract:Yang Xu, 1, &ast Yue Wu, 1, &ast Jianhong Liu, 2 Lili Xiao, 1 Ying Zhang 1 1 Department of Gastroenterology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, 163000, People's Republic of China; 2 Department of Breast and Thyroid Surgery, Daqing Oilfield General Hospital, Daqing, Heilongjiang, 163000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Ying Zhang, Email Background: The study explored the prognostic value of caudal-type homeobox transcription factor 2 (CDX2) in stage II and III gastric cancer. Methods: This study evaluated the expression level of CDX2 in gastric cancer in a hospital cohort (n=197) using immunohistochemistry. According to a semiquantitative score used to determine CDX2 expression, the cases were divided into a low CDX2 group (116 cases) and a high CDX2 group (81 cases). The RNA-seq expression data from 291 patients with stage II and III gastric cancer from The Cancer Genome Atlas (TCGA) cohort were used to verify the immunohistochemistry results. Based on the median CDX2 expression value, the TCGA patients were divided into a low CDX2 group (145 cases) and a high CDX2 group (146 cases). The relationships among CDX2 expression and clinicopathological features were determined using the Chi-square test. Cox proportional hazards regression models were applied to estimate the independent prognostic factors. The probability of survival was determined using the Kaplan-Meier method and Log rank tests. Results: Based on the Cox multivariate analysis, CDX2 was the independent prognostic factor in the hospital and TCGA cohorts. In the hospital cohort, CDX2 expression was associated with an improved DFS (hazard ratio [HR] = 0.4076, 95% CI, 0.2675– 0.6210, P = 0.0001) and OS (HR = 0.4183, 95% CI, 0.2744– 0.6375, P = 0.0002). In the TCGA cohort, CDX2 expression also was associated with an improved DFS (HR = 0.5948, 95% CI, 0.4153– 0.8521, P = 0.0054) and OS (HR = 0.5976, 95% CI, 0.4172– 0.8561, P = 0.0058). Furthermore, the CDX2 expression level was correlated with an improved DFS ( P = 0.0025) and OS ( P = 0.0015) using the Kaplan-Meier Plotter database for gastric cancer. Conclusion: CDX2 is a potential prognostic biomarker for stage II and III gastric cancer. In addition, CDX2 positive cancer patients are more likely to have resectable tumors and exhibit better survival rates. Keywords: gastric cancer, CDX2, immunoreactivity, chemotherapy, prognostic marker Gastric cancer is the sixth most common malignant tumor and the third cause of cancer-related death worldwide. 1 Global Cancer Statistics 2020 indicates that 1,089,103 new cases are diagnosed, and 768,793 people will die from this disease. 1 Gastric cancer is more common in the Asia Pacific regions, especially in Japan, South Korea, and East Asia. 2 China is a large East Asian country with a high death rate due to gastric cancer. 3 Notably, the incidence and mortality rates for gastric cancer classified by age have steadily decreased. 4 Gastric cancer is often diagnosed at more advanced stages, usually because the initial symptoms are non-specific or overlooked. 5 Based on the stage and tumor location, patients typically are treated with surgery, chemotherapy, and radiotherapy, and the invasiveness of the disease depends on the tumor differentiation. 6 However, patients with stage IV gastric cancer usually are considered inoperable. In the past decade, the survival rate of resectable stage II and III gastric cancer patients has improved to some degree due to the introduction of adjuvant treatment. 7 Nevertheless, the current treatment protocols fail to achieve substantial curative benefits. The lack of convenient and reliable standards to provide accurate prognoses for patients with resectable stage II and III gastric cancer makes it difficult to identify patients who are most likely to benefit from adjuvant or salvage treatment. Caudal-type homeobox transcription factor 2 (CDX2) is a transcription factor involved in intestinal cell proliferation and differentiation and primarily regulates the intestinal function of progenitor cells. 8–10 CDX2 is expressed in intestinal epithelial cells of adult mammals from the proximal duodenum to the distal rectum. 11,12 The absence of CDX2 expression is related to the prognosis of patients with colorectal carcinoma. 13–15 Yu and colleagues have shown that CDX2 inhibited colon cancer cell proliferation by restricting Wnt/β-catenin signaling. 16 Tomasello et al demonstrated that the expr -Abstract Truncated-
medicine, general & internal